Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B

There are few studies comparing the safety and immunogenicity of the same HIV immunogen in healthy volunteers and HIV-infected individuals. We analyzed demographics, adverse events (AEs), and immunogenicity against vaccinia virus in preventive (RISVAC02, <i>n</i> = 24 low-risk HIV-negati...

Full description

Bibliographic Details
Main Authors: Elvira Couto, Vicenç Diaz-Brito, Beatriz Mothe, Alberto C. Guardo, Irene Fernandez, Ainoa Ugarte, Flor Etcheverry, Carmen E. Gómez, Mariano Esteban, Judit Pich, Joan Albert Arnaiz, Juan Carlos López Bernaldo de Quirós, Christian Brander, Montserrat Plana, Felipe García, Lorna Leal
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Vaccines
Subjects:
vaccine
hiv-1
preventive
therapeutic
mva-b
Online Access:https://www.mdpi.com/2076-393X/7/4/178

Internet

https://www.mdpi.com/2076-393X/7/4/178

Similar Items